Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: Relevance of Breast Cancer Subtype

Journal of Clinical Oncology

Volumn 29, Issue 6, 2011, Pages 660-666

  Loo, Claudette E ^a   Straver, Marieke E ^a   Rodenhuis, Sjoerd ^a   Muller, Sara H ^a   Wesseling, Jelle ^a   Vrancken Peeters, Marie Jeanne T F D ^a   Gilhuijs, Kenneth G A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; PACLITAXEL; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ASSESSMENT; CONTRAST ENHANCEMENT; DISEASE SEVERITY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MORPHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; RATING SCALE; TREATMENT RESPONSE; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BREAST NEOPLASMS; FEMALE; GENES, ERBB-2; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM, RESIDUAL; RECEPTORS, ESTROGEN; YOUNG ADULT;

EID: 79952134557     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.31.1258     Document Type: Article

References (34)

1. Wolmark N, Wang J, Mamounas E, et al: Preoperative chemotherapy in patients with operable breast cancer: Nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 30:96-102, 2001
2. Fisher B, Brown A, Mamounas E, et al: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15:2483-2493, 1997 (Pubitemid 27289876)
3. Fisher ER, Wang J, Bryant J, et al: Pathobiology of preoperative chemotherapy: Findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer 95:681-695, 2002 (Pubitemid 34845919)
4. Rastogi P, Anderson SJ, Bear HD, et al: Preoperative chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 26:778-785, 2008 (Pubitemid 351264391)
5. Chollet P, Amat S, Cure H, et al: Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer 86:1041-1046, 2002 (Pubitemid 34441058)
6. van der Hage JA, van de Velde CJ, Julien JP, et al: Preoperative chemotherapy in primary operable breast cancer: Results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 19:4224-4237, 2001
7. Denley H, Pinder SE, Elston CW, et al: Preoperative assessment of prognostic factors in breast cancer. J Clin Pathol 54:20-24, 2001 (Pubitemid 32048290)
8. Rakha EA, El-Sayed ME, Green AR, et al: Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol 25:4772-4778, 2007 (Pubitemid 350086480)
9. Chuthapisith S, Eremin JM, Eremin O: Predicting response to neoadjuvant chemotherapy in breast cancer: Molecular imaging, systemic biomarkers and the cancer metabolome. Oncol Rep 20: 699-703, 2008
10. Desmedt C, Haibe-Kains B, Wirapati P, et al: Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 14:5158-5165, 2008
11. Sánchez-Muñoz A, García-Tapiador AM, Martinez-Ortega E, et al: Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Clin Transl Oncol 10:646-653, 2008
12. de Ronde JJ, Hannemann J, Halfwerk H, et al: Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. Breast Cancer Res Treat 119:119-126, 2010
13. Nicholson RI, Johnston SR: Endocrine therapy: Current benefits and limitations. Breast Cancer Res Treat 93:S3-S10, 2005 (suppl 1)
14. Tokunaga E, Oki E, Nishida K, et al: Trastuzumab and breast cancer: Developments and current status. Int J Clin Oncol 11:199-208, 2006 (Pubitemid 44087118)
15. Loo CE, Teertstra HJ, Rodenhuis S, et al: Dynamic contrast-enhanced MRI for prediction of breast cancer response to neoadjuvant chemotherapy: Initial results. Am J Roentgenol 191:1331-1338, 2008
16. Manton DJ, Chaturvedi A, Hubbard A, et al: Neoadjuvant chemotherapy in breast cancer: Early response prediction with quantitative MR imaging and spectroscopy. Br J Cancer 94:427-435, 2006 (Pubitemid 43237566)
17. Padhani AR, Hayes C, Assersohn L, et al: Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: Initial clinical results. Radiology 239:361-374, 2006
18. Pickles MD, Lowry M, Manton DJ, et al: Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy. Breast Cancer Res Treat 91:1-10, 2005 (Pubitemid 40684933)
19. Buzdar AU, Ibrahim NK, Francis D, et al: Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23:3676-3685, 2005
20. Straver ME, Rutgers EJ, Rodenhuis S, et al: The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy. Ann Surg Oncol 17:2411-2418, 2010
21. Hannemann J, Oosterkamp HM, Bosch CA, et al: Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 23:3331-3342, 2005
22. Gilhuijs KG, Deurloo EE, Muller SH, et al: Breast MR imaging in women at increased lifetime risk of breast cancer: Clinical system for computerized assessment of breast lesions initial results. Radiology 225:907-916, 2002 (Pubitemid 35387133)
23. American College of Radiology: Breast Imaging and Reporting Data System (BI-RADS). Reston, VA, American College of Radiology, 2003
24. Rodenhuis S, Mandjes IA, Wesseling J, et al: A simple system for grading the response of breast cancer to neoadjuvant chemotherapy. Ann Oncol 21:481-487, 2010
25. Honkoop AH, van Diest PJ, de Jong JS, et al: Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br J Cancer 77:621-626, 1998 (Pubitemid 28059470)
26. Uematsu T, Kasami M, Yuen S: Triple-negative breast cancer: Correlation between MR imaging and pathologic findings. Radiology 250:638-647, 2009
27. Chen JH, Agrawal G, Feig B, et al: Triple-negative breast cancer: MRI features in 29 patients. Ann Oncol 18:2042-2043, 2007 (Pubitemid 350286248)
28. Wang Y, Ikeda DM, Narasimhan B, et al: Estrogen receptor-negative invasive breast cancer: Imaging features of tumors with and without human epidermal growth factor receptor type 2 overexpression. Radiology 246:367-375, 2008
29. Chen JH, Feig B, Agrawal G, et al: MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy. Cancer 112:17-26, 2008
30. Moon HG, Han W, Lee JW, et al: Age and HER2 expression status affect MRI accuracy in predicting residual tumor extent after neo-adjuvant systemic treatment. Ann Oncol 20:636-641, 2009
31. Perou CM, Sørlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406:747-752, 2000
32. Hu Z, Fan C, Oh DS, et al: The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7:96, 2006
33. Carey LA, Dees EC, Sawyer L, et al: The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13:2329-2334, 2007 (Pubitemid 46698581)
34. von Minckwitz G, Kümmel S, Vogel P, et al: Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: Phase III randomized GeparTrio trial. J Natl Cancer Inst 100:542-551, 2008